Novartis Balance Sheet Analysis From 2010 to 2024
NVS Stock | USD 98.35 1.07 1.10% |
Novartis |
Most indicators from Novartis' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Novartis Valuation and Novartis Correlation analysis. At this time, Novartis' Selling General Administrative is comparatively stable compared to the past year. Discontinued Operations is likely to gain to about 5.5 B in 2024, whereas Enterprise Value is likely to drop slightly above 107.4 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 37.0B | 36.3B | 34.2B | 32.3B | Total Revenue | 52.9B | 51.8B | 46.7B | 46.2B |
Novartis fundamental ratios Correlations
Click cells to compare fundamentals
Novartis Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novartis fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 118.4B | 132.1B | 131.8B | 117.5B | 99.9B | 103.1B | |
Other Current Liab | 15.4B | 17.5B | 18.0B | 17.2B | 15.1B | 11.4B | |
Net Debt | 18.2B | 28.4B | 18.7B | 20.4B | 13.0B | 11.0B | |
Retained Earnings | 59.3B | 57.2B | 71.0B | 63.5B | 49.6B | 57.8B | |
Accounts Payable | 5.4B | 5.4B | 5.6B | 5.1B | 4.9B | 4.2B | |
Cash | 11.1B | 9.7B | 12.4B | 7.5B | 13.4B | 7.7B | |
Net Receivables | 8.6B | 8.5B | 8.3B | 8.3B | 9.4B | 8.8B | |
Inventory | 6.0B | 7.1B | 6.7B | 7.2B | 5.9B | 6.0B | |
Other Current Assets | 2.7B | 2.5B | 2.4B | 2.5B | 1.2B | 2.2B | |
Total Liab | 62.8B | 75.4B | 64.0B | 58.0B | 53.2B | 45.6B | |
Total Current Assets | 29.5B | 29.7B | 45.7B | 36.9B | 30.5B | 29.9B | |
Capital Stock | 936M | 913M | 901M | 890M | 825M | 767.6M | |
Short Term Debt | 7.3B | 10.1B | 6.6B | 6.2B | 6.3B | 6.3B | |
Common Stock | 936M | 913M | 901M | 890M | 825M | 767.6M | |
Intangible Assets | 28.8B | 36.8B | 34.2B | 31.6B | 26.9B | 22.4B | |
Other Liab | 12.5B | 14.4B | 9.2B | 7.6B | 8.7B | 8.5B | |
Other Assets | 14.8B | 14.7B | 12.4B | 4.8B | 5.6B | 10.1B | |
Long Term Debt | 20.4B | 26.3B | 22.9B | 20.2B | 18.4B | 12.8B | |
Good Will | 26.5B | 30.0B | 29.6B | 29.3B | 23.3B | 22.0B | |
Treasury Stock | (69M) | (80M) | (53M) | (48M) | (41M) | (43.1M) | |
Net Tangible Assets | 5.6B | (5.5B) | 9.4B | 2.8B | 2.5B | 2.4B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Novartis Valuation and Novartis Correlation analysis. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.215 | Dividend Share 3.919 | Earnings Share 4.1 | Revenue Per Share 23.168 | Quarterly Revenue Growth 0.097 |
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.